NCT06714825View on ClinicalTrials.gov

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 28, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Overweight and Obesity
Interventions
BIOLOGICAL

HS235

Up to 4 Single and 3 Multiple Ascending Doses

DRUG

Placebo

Subcutaneous Injection

Trial Locations (1)

Unknown

RECRUITING

Syneos Clinical Research Unit, Québec

Sponsors

Lead Sponsor

35Pharma Inc
All Listed Sponsors
lead

35Pharma Inc

INDUSTRY